RVD with weekly subcutaneous bortezomib minimizes neuropathy and maintains efficacy in a diverse multiple myeloma cohort

被引：1
|
作者：
Gill, Amitoj [1 ]
Jayswal, Rani [2 ]
Weiss, Heidi [2 ]
Rhodes, Jill [1 ]
Hegazi, Mohamed [1 ]
Herzig, Geoffrey [1 ]
Herzig, Roger [2 ]
Krem, Maxwell [2 ]
机构：
[1] Univ Louisville, Louisville, KY 40292 USA
[2] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
bortezomib; neuropathy; Tolerability;
D O I：
10.1016/j.clml.2019.09.349
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SP-023
引用
收藏
页码：E210 / E210
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of subcutaneous bortezomib versus intravenous bortezomib in patients with multiple myeloma: a systematic review and meta-analysis
    Zhang, Shilong
    Li, Jing
    Liu, Peng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (02): : 445 - +
  • [32] Prospective comparison of subcutaneous to intravenous administration of bortezomib in patients with multiple myeloma: Pharmacokinetics, efficacy and toxicity
    Moreau, P.
    Coiteux, V.
    Hulin, C.
    Facon, T.
    van de Velde, H.
    Acharya, M.
    Harousseau, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] SAFETY AND EFFICACY OF SUBCUTANEOUS VERSUS INTRAVENOUS BORTEZOMIB IN PATIENTS WITH NEWLY ELDERLY DIAGNOSED MULTIPLE MYELOMA
    Bacchiarri, F.
    Nozzoli, C.
    Antonioli, E.
    Staderini, M.
    Barone, F.
    Guarrera, A.
    Messeri, M.
    Coltro, G.
    Grieco, P.
    Bosi, A.
    HAEMATOLOGICA, 2017, 102 : 167 - 167
  • [34] Prospective comparison of subcutaneous vs intravenous administration of bortezomib in patients with multiple myeloma: Pharmacokinetics, efficacy and
    Moreau, P.
    Coiteux, V.
    Hulin, C.
    Facon, T.
    van de Velde, H.
    Acharya, M.
    Harousseau, J. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 158 - 158
  • [35] EFFICACY AND SAFETY OF THREE SUBCUTANEOUS BORTEZOMIB COMBINATIONS IN ELDERLY, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Cerrato, C.
    Oliva, S.
    Petrucci, M. T.
    Caraffa, P.
    Nozzoli, C.
    Finsinger, P.
    Larocca, A.
    De Rosa, L.
    De Paoli, L.
    Montefusco, V.
    Saraci, E.
    Villani, O.
    Carella, A. M.
    Benevolo, G.
    Morabito, F.
    Liberati, A. M.
    Derudas, D.
    Boccadoro, M.
    Sonneveld, P.
    Palumbo, A.
    HAEMATOLOGICA, 2014, 99 : 107 - 107
  • [36] Assessing efficacy and tolerability of a modified lenalidomide/bortezomib/dexamethasone (VRd-28) regimen using weekly bortezomib in multiple myeloma
    Rodriguez, Cesar
    Lantz, Jeffrey
    Akbar, Faisal
    Lantz, Lyndsey
    Dressler, Emily
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E217 - E218
  • [37] Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)
    Joseph, Nisha
    Almaula, Dhwani
    Gleason, Charise
    Heffner, Leonard
    Boise, Lawrence H.
    Kaufman, Jonathan L.
    Lonial, Sagar
    Nooka, Ajay
    BLOOD, 2017, 130
  • [38] Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma
    Merz, Maximillan
    Salwender, Hans-Juergen
    Haenel, Mathias
    Bertsch, Uta
    Kunz, Christina
    Hielscher, Thomas
    Blau, Igor W.
    Scheid, Christof
    Mai, Elias Karl
    Hose, Dirk
    Schurich, Baerbel
    Munder, Markus
    Brossart, Peter
    Gerecke, Christian
    Lindemann, Hans Walter
    Zeis, Matthias
    Weisel, Katja C.
    Duerig, Jan
    Goldschmidt, Hartmut
    BLOOD, 2015, 126 (23)
  • [39] DOMESTIC SUBCUTANEOUS SELF-INJECTION OF BORTEZOMIB IN MULTIPLE MYELOMA
    Cerchione, C.
    Madonna, E.
    Fabbricini, R.
    Marano, L.
    Pugliese, N.
    Avilia, S.
    Cerciello, G.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2013, 98 : 597 - 598
  • [40] DOMESTIC SUBCUTANEOUS SELF-INJECTION OF BORTEZOMIB IN MULTIPLE MYELOMA
    Cerchione, C.
    Nappi, D.
    Migliaccio, I.
    Salvatore, D.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2016, 101 : 801 - 801
12345